Acquisition by Moulder Leon O Jr of 2500 shares of Zenas BioPharma, at 14.57 subject to Rule 16b-3
| ZBIO Etf | USD 9.25 0.09 0.98% |
About 56% of Zenas BioPharma,'s investor base is looking to short. The analysis of overall sentiment of trading Zenas BioPharma, Common etf suggests that many investors are alarmed at this time. Zenas BioPharma,'s investing sentiment overview a quick insight into current market opportunities from investing in Zenas BioPharma, Common. Many technical investors use Zenas BioPharma, Common etf news signals to limit their universe of possible portfolio assets and to time the market correctly.
Zenas |
Filed transaction by Zenas BioPharma, Common Director, Officer: Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Zenas BioPharma, Fundamental Analysis
We analyze Zenas BioPharma,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zenas BioPharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zenas BioPharma, based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Zenas BioPharma, is currently under evaluation in net asset as compared to similar ETFs. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Zenas BioPharma, Common Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zenas BioPharma, etf to make a market-neutral strategy. Peer analysis of Zenas BioPharma, could also be used in its relative valuation, which is a method of valuing Zenas BioPharma, by comparing valuation metrics with similar companies.
Peers
Zenas BioPharma, Related Equities
| ENTO | Entero Therapeutics, | 6.78 | ||||
| ENTX | Entera Bio | 1.79 | ||||
| ENLV | Enlivex Therapeutics | 3.97 | ||||
| ELVN | Enliven Therapeutics | 4.49 | ||||
| ELTX | Elicio Therapeutics | 6.20 | ||||
| ELEV | Elevation Oncology | 6.94 | ||||
| DWTX | Dogwood Therapeutics, | 9.74 | ||||
| ENSC | Ensysce Biosciences | 9.87 | ||||
| ENTA | Enanta Pharmaceuticals | 10.14 | ||||
| ENGN | EnGene Holdings | 13.14 |
Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.